Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer

Laura Pons, Laura Hernández, Aintzane Urbizu, Paula Osorio, Paula Rodríguez-Martínez, Eva Castella, Ana Muñoz, Carolina Sanz, Laura Arnaldo, Eudald Felip, Vanesa Quiroga, Gustavo Tapia, Mireia Margelí, Pedro Luis Fernandez*

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

2 Citas (Scopus)

Resumen

Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correlation of clinicopathological factors with pCR was studied in 150 patients (HER2 = 81; TN = 69) and pre- and post-NAT differences in tumour biomarkers were compared. Low estrogen receptor (ER) expression, high tumour-infiltrating lymphocytes (TILs) and low cT-stage were associated with pCR in HER2+ tumours (p = 0.022; p = 0.032 and p = 0.005, respectively). Furthermore, ER expression was also associated with residual cancer burden (RCB; p = 0.046) in the HER2+ subtype. Similarly, pre-NAT, low progesterone receptor expression (PR; 1–10%) was associated with higher RCB (p < 0.001) in TN tumours. Only clinical and pathological T-stage (cpT-stage) had prognostic capacity in HER2+ tumours, whereas pre-NAT cpT-stage and post-NAT TILs had this capacity for the prognosis of TN tumours. We conclude that ER and PR expression may help predict response to NAT in HER2 and TN BC and should be taken into account in residual tumours. Also, changes observed in the phenotype after NAT suggest the need to reevaluate biomarkers in surviving residual tumour cells.
Idioma originalInglés
Número de artículo3068
Número de páginas19
PublicaciónCancers
Volumen15
N.º12
DOI
EstadoPublicada - 6 jun 2023

Palabras clave

  • Breast cancer
  • Neoadjuvant chemotherapy
  • HER2+
  • Triple negative

Huella

Profundice en los temas de investigación de 'Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer'. En conjunto forman una huella única.

Citar esto